… [6] Oral valganciclovir and intravenous ganciclovir recipients had similar tolerability
profiles with the exception of catheter-related infection which occurred more frequently in …

… In conclusion, for solid organ transplant recipients with CMV disease, oral valganciclovir
has comparable safety and is not inferior to standard iv ganciclovir treatment for eradication of …

… In this study, oral valacyclovir and intravenous ganciclovir had similar efficacies for prevention
of CMV disease in allogeneic BMT recipients. There were only 2 cases of CMV disease in …

… oral valganciclovir with intravenous ganciclovir [7]. The mean values for the AUC 0-∞ and
AUC 0-t of ganciclovir after dosing with 900 mg of oral valganciclovir … 900 mg of valganciclovir. …

… Valganciclovir (V-GCV) is an oral prodrug hydrolyzed to the anti-CMV drug ganciclovir (GCV…
trial compared exposure to GCV after V-GCV and intravenous GCV (IV-GCV) as preemptive …

… ganciclovir pharmacokinetics, following intravenous ganciclovir and oral valganciclovir …
All children aged <18 years receiving ganciclovir or valganciclovir were included in this study. …

… to GCV after po valganciclovir with respect to IV GCV … valganciclovir showed comparable
values (P=0.054). This short course, combining initial IV GCV and subsequent po valganciclovir…

… course of intravenous ganciclovir followed by oral valganciclovir: … Oral ganciclovir and
pharmacokinetics of valganciclovir in … Valganciclovir for cytomegalovirus prevention in solid organ …

… of an orally administered valine ester of ganciclovir (GCV), valganciclovir (VGC), were
studied. These were compared to the pharmacokinetics of oral and intravenous GCV. Twenty-…

… Derived pharmacokinetic parameters 1 of ganciclovir in pediatric renal or liver transplant
recipients following treatment with oral valganciclovir and intravenous ganciclovir, by age group …